The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer

Gynecologic Oncology

Volumn 61, Issue 1, 1996, Pages 22-26

  Gogas, H ^a   Shapiro, F ^a   Aghajanian, C ^a   Fennelly, D ^a   Almadrones, L ^a   Hoskins, W J ^a   Spriggs, D R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; DEXAMETHASONE; GLUCOSE; PACLITAXEL;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CANCER; PRIORITY JOURNAL; SENSORY NEUROPATHY;

EID: 0029970249     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0090     Document Type: Article

References (23)

1. Donehower, R. C., Rowinsky, E. K., Grochow, L. B., Longnecker, S. M., and Ettinger, D. S. Phase I trial of taxol in patients with advanced cancer, Cancer Treat. Rep. 71, 1171-1177 (1987).
2. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., and Donehower, R. C. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms, Ann. Intern. Med. 111, 273-279 (1989).
3. Sarosy, G., Kohn, E., Stone, D. A., Rothenberg, M., Jacob, J., Adamo, D. O., Ognibene, F. P., Cunnion, R. E., and Reed, E. Phase study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer, J. Clin. Oncol. 20, 1165-1170 (1992).
4. Thigpen, T. J., Blessing, S. A., Ball, H., Hummell, S. J., and Barrett, R. J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study, J. Clin. Oncol. 12, 1748-1753 (1994).
5. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med. 334, 1-6 (1996).
6. Rowinsky, E. K., Chaudhry, V., Forastiere, A. A., Sartorius, S. E., Ettinger, D. S., Grochow, L. B., Lubejko, B. G., Cornblath, D. R., and Donehower, R. C. A phase I and pharmacologic study of taxol and cisplatin with granulocyte colony-stimulating factor neuromuscular toxicity is dose limiting, J. Clin. Oncol. 11, 2010-2020 (1993).
7. Mollman, J. E. Cisplatin neurotoxicity, N. Engl. J. Med. 322, 126-127 (1990).
8. Roelofs, R. I., Hurshesky, W., Rogin, J., and Rosenberg, L. Peripheral sensory neuropathy and cisplatin chemotherapy, Neurology 34, 934-938 (1984).
9. Rosenfeld, C. S., and Broder, L. E. Cisplatin-induced autonomie neuropathy, Cancer Treat. Rep. 68, 659-660 (1984).
10. Cohen, S. C., and Mollman, J. E. Cisplatin-induced gastric paresis, J. Neurol. Oncol. 5, 237-240 (1987).
11. Gershenson, D. M., Wharton, T., Herson, J., Edwards, C. L., and Rutledge, F. N. Single-agent cisplatin therapy for advanced ovarian cancer, Obstet. Gynecol. 58, 487-496 (1981).
12. Mollman, S. E., Glover, D. J., Hogan, W. M., and Furman, R. E. Cisplatin neuropathy: Risk factors, prognosis and protection by WR-2721, Cancer 61, 2192-2195 (1988).
13. Walczak, J. R., Almadrones, L., and Brady, M. Assessment of peripheral neuropathy and physical role functioning in a phase III randomized chemotherapy trial in the Gynecologic Oncology Group (GOG), Proceedings of the Oncology Nursing Society, 1995, Oncol. Nurs. Forum 22, 197 (1995). [Abstract]
14. Schiller, J. H., Storer, B., Tutsch, K., Arzoomanian, R., Alberti, D., Feierabend, C., and Spriggs, D. A phase I trial of 3-hour infusions of paclitaxel (taxol) with or without granulocyte colony-stimulating factor, Semin. Oncol. 21, 9-14 (1994).
15. Gregory, E. R., and DeLisa, A. F. A paclitaxel: A new antineoplastic agent for refractory ovarian cancer, Clin. Pharm. 12, 401-15 (1993).
16. Forastiere, A., Rowinsky, E., Chaudhry, V., Sartorius, S., Lubejko, B., Ettinger, D., Grochow, L., and Donehower, R. Phase I and pharmacologic study of taxol and cisplatin and G-CSF, Proc. Am. Soc. Clin. Oncol. 11, 117 (1992). [Abstract]
17. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., and Donehower, R. C. Sequences of taxol and cisplatin: A phase I and pharmacologic study, J. Clin. Oncol. 9, 1692-1703 (1991).
18. Wiernik, P. H., Schwartz, E. L., Einzig, A., Strauman, J. J., Lipton, R. B., and Dutcher, J. B. Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma, J. Clin. Oncol. 5, 1232-1239 (1987).
19. Van Der Hoop, G. R., Van Der Burg, M. E. L., Ten Bokkel Huinink, W. W., Van Houwelinger, J. C., and Neijt, J. P. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin, Cancer 66, 1697-1702 (1990).
20. Cascinu, S., Cordella, L., Delferro, E., Fronzoni, M., and Catalano, G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial, J. Clin. Oncol. 13, 26-32 (1995).
21. Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., and Cornblath, D. R. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies, Ann. Neurol. 35, 304-311 (1994).
22. Brown, T., Havlin, G., Weiss, J., Cagnola, J., Koeller, J., Kuhn, J., Rizzo, J., Craig, J., Phillips, J., and Von Hoff, D. A phase I trial of taxol given by a 6-hour intravenous infusion, J. Clin. Oncol. 9, 1261-7 (1991).
23. Jerian, S. M., Sarosy, G. A., Link, C. J., Fingert, H. J., Reed, E., and Kohn, E. C. Incapacitating autonomie neuropathy precipitating by taxol: Case report, Gynecol. Oncol. 51, 277-280 (1993).